retro.jpg
Retrotope Announces Completion of Enrollment in Phase 2 Study of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)
April 21, 2021 07:00 ET | Retrotope
LOS ALTOS, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases,...
retro.jpg
Retrotope Announces Initiation of Phase 2 Study of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)
March 17, 2021 07:00 ET | Retrotope
LOS ALTOS, Calif., March 17, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases,...
retro.jpg
Retrotope to Present at H.C. Wainwright Global Life Sciences Conference
March 03, 2021 16:05 ET | Retrotope
LOS ALTOS, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases,...
retro.jpg
Retrotope Granted Rare Pediatric Disease Designation from FDA for Lead Development Candidate, RT001, in Two Life-Threatening Neurodegenerative Indications
February 25, 2021 07:00 ET | Retrotope
Company Currently Conducting Late-Stage Clinical Trials in Both Infantile Neuroaxonal Dystrophy (INAD) and Friedreich’s Ataxia (FA) RT001 also Granted Fast Track Designation by FDA in FA; Orphan Drug...
retro.jpg
Retrotope Expands its Drug Pipeline with the First Dosing of RT001 in patients with Friedreich’s ataxia (FA)
January 09, 2020 10:24 ET | Retrotope
LOS ALTOS, Calif., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Retrotope announced today that it has dosed its first patient in a Phase 2/3 clinical trial of RT001 in Friedreich’s ataxia, the most common of...
retro.jpg
Retrotope Announces Full Enrollment of Phase 2/3 trial in patients with Infantile Neuroaxonal Dystrophy (INAD)
August 07, 2019 10:00 ET | Retrotope
LOS ALTOS, Calif., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Retrotope announced today that it has fully enrolled all patients in the first clinical trial of a possible treatment for infants with the...
retro.jpg
Retrotope Announces RT001 Clinical Data Presentation at the 2019 American Academy of Neurology (AAN) Annual Meeting
May 06, 2019 12:57 ET | Retrotope
LOS ALTOS, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Retrotope announced today positive findings from an expanded access study of the company’s lead candidate, RT001, in a patient with LOTS, as...
retro.jpg
EMA Grants Orphan Medicinal Product Designation for Retrotope’s RT001 in the Treatment of Infantile Neuroaxonal Dystrophy (INAD), a PLA2G6 associated neurodegeneration (PLAN)
March 13, 2019 13:23 ET | Retrotope
LOS ALTOS, Calif., March 13, 2019 (GLOBE NEWSWIRE) -- Retrotope received notification from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) that its request for...